Gentian USA Inc
In combining 20+ years of industry experience with unique and proprietary technologies, Gentian has established itself as a leader in Particle-Enhanced Turbidimetric Immunoassay (PETIA) development. Gentian’s goal is to increase diagnostic efficiency and decrease the cost of diagnostic testing in areas including kidney, infectious, inflammatory and cardiovascular diseases. The current portfolio includes cystatin C (510(k)-cleared/CE marked), plasma calprotectin (CE marked/US research use only), canine CRP and fecal calprotectin assays with more under development.
Gentian products can be used without additional investment in instrumentation because our assays are designed for use on all major clinical chemistry analyzers. Production, R&D, marketing and distribution of immunoassays are performed at our headquarters in Norway and are supported globally by subsidiaries and our representative office in China.
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
No